Vir Biotechnology, Inc. Stock price

Equities

VIR

US92764N1028

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
10.13 USD +0.30% Intraday chart for Vir Biotechnology, Inc. +0.40% +0.70%
Sales 2024 * 41.41M Sales 2025 * 41.59M Capitalization 1.37B
Net income 2024 * -571M Net income 2025 * -585M EV / Sales 2024 * 14.7 x
Net cash position 2024 * 758M Net cash position 2025 * 681M EV / Sales 2025 * 16.5 x
P/E ratio 2024 *
-2.41 x
P/E ratio 2025 *
-2.55 x
Employees 587
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.71%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines MT
Vir Biotechnology, GSK Terminate Collaboration on Flu DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA CI
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer CI
HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating MT
North American Morning Briefing : Microsoft Kicks -2- DJ
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23 MT
Transcript : Vir Biotechnology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Vir Biotechnology to Eliminate Roles, Close Facilities to Cut Costs MT
More news
1 day+0.30%
1 week+0.40%
Current month-9.88%
1 month-12.67%
3 months-1.55%
6 months+9.99%
Current year+0.70%
More quotes
1 week
9.78
Extreme 9.78
10.34
1 month
9.77
Extreme 9.77
11.76
Current year
8.42
Extreme 8.415
12.00
1 year
7.72
Extreme 7.72
27.48
3 years
7.72
Extreme 7.72
58.00
5 years
7.72
Extreme 7.72
141.01
10 years
7.72
Extreme 7.72
141.01
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 -
Director of Finance/CFO 53 23-03-26
Chief Tech/Sci/R&D Officer - Nov. 05
Members of the board TitleAgeSince
Director/Board Member 72 20-07-01
Director/Board Member 59 16-12-31
Director/Board Member 56 16-08-31
More insiders
Date Price Change Volume
24-03-28 10.13 +0.30% 738,256
24-03-27 10.1 +1.30% 995,069
24-03-26 9.97 -0.30% 603,634
24-03-25 10 -0.50% 442,588
24-03-22 10.05 -0.40% 511,002

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
10.13 USD
Average target price
29.5 USD
Spread / Average Target
+191.21%
Consensus
  1. Stock
  2. Equities
  3. Stock Vir Biotechnology, Inc. - Nasdaq